- Home
- NEA vs VERA Comparison
NEA vs VERA Comparison
Compare NEA & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEA
- VERA
- Stock Information
- Founded
- NEA 2002
- VERA 2016
- Country
- NEA United States
- VERA United States
- Employees
- NEA N/A
- VERA N/A
- Industry
- NEA Finance/Investors Services
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- NEA Finance
- VERA Health Care
- Exchange
- NEA Nasdaq
- VERA Nasdaq
- Market Cap
- NEA 3.3B
- VERA 2.7B
- IPO Year
- NEA N/A
- VERA 2021
- Fundamental
- Price
- NEA $11.25
- VERA $33.37
- Analyst Decision
- NEA
- VERA Buy
- Analyst Count
- NEA 0
- VERA 8
- Target Price
- NEA N/A
- VERA $63.50
- AVG Volume (30 Days)
- NEA 803.4K
- VERA 749.7K
- Earning Date
- NEA 01-01-0001
- VERA 11-07-2024
- Dividend Yield
- NEA 4.23%
- VERA N/A
- EPS Growth
- NEA N/A
- VERA N/A
- EPS
- NEA N/A
- VERA N/A
- Revenue
- NEA N/A
- VERA N/A
- Revenue This Year
- NEA N/A
- VERA N/A
- Revenue Next Year
- NEA N/A
- VERA N/A
- P/E Ratio
- NEA N/A
- VERA N/A
- Revenue Growth
- NEA N/A
- VERA N/A
- 52 Week Low
- NEA $9.20
- VERA $14.20
- 52 Week High
- NEA $11.37
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- NEA 41.48
- VERA 22.57
- Support Level
- NEA $11.15
- VERA $31.77
- Resistance Level
- NEA $11.31
- VERA $36.28
- Average True Range (ATR)
- NEA 0.11
- VERA 2.18
- MACD
- NEA 0.01
- VERA -0.86
- Stochastic Oscillator
- NEA 51.04
- VERA 13.34
About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.